Agios Pharmaceuticals(NASDAQ: AGIO) stock rose by 13.8% during the week through Friday morning. It's a move driven by the ...
The company is trying again after receiving a complete response letter from the FDA last year requested more data.
Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sickle cell disease, with a ...
Today, a brief rundown of news involving Prime Medicine and Saol Therapeutics, as well as updates from Revolution Medicines and Cyllene Therapeutics that you may have missed.
3d
Agios Pharmaceuticals Shares Rise After FDA Grants Priority Review for Sickle Cell Disease Treatment
Agios Pharmaceuticals shares rose Tuesday after the U.S. Food and Drug Administration granted priority review to the company's supplemental new drug application for mitapivat to treat sickle cell ...
New research finds that birds can use lactate, often thought of as a metabolic waste product, as a cellular fuel that aids in ...
Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SL1009 ...
Agios Pharmaceuticals (AGIO) stock rises as the U.S. FDA grants priority review for the company's bid to seek a label ...
FDA’s PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell ...
FDA's PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results